TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Cervomed Inc.
CervoMed Presents New Plasma Biomarker Data That Indicates Neflamapimod Broadly Improves Neuroinflammation and Neurodegeneration in Dementia with Lewy Bodies (DLB)

CervoMed shared Phase 2b trial data showing neflamapimod treatment reduced neuroinflammation biomarkers in Dementia with Lewy Bodies patients, with promising results indicating potential disease progression slowing.

Insights
FpB   negative

Mentioned as a rival potentially hurt by changes in EV market incentives


CRVO   positive

Presented promising Phase 2b trial results demonstrating potential treatment effectiveness for Dementia with Lewy Bodies, with significant biomarker reductions and plans to advance to Phase 3 trials